DaShenLin Pharmaceutical Group Co (603233.SS) Stock Price

DaShenLin Pharmaceutical Group Co Price

SSE·CLOSED
17.94CNY-0.34 (-1.88 %)
Market closed

Revenue has compounded at 19.3% per year over the past 10 years to 26.50 B CNY. Earnings per share have grown at 4.4% per year over the last 10 years. DaShenLin Pharmaceutical Group Co's net margin stands at 3.5%, down from 7.3% several years earlier. DaShenLin Pharmaceutical Group Co currently offers a dividend yield of about 3.46%. The payout ratio is around 77% of earnings. The dividend has grown at 0.5% per year over the past 6 years. Analysts set a median price target of 24.48 CNY, implying 36.5% above the current price. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 21% above its 52-week low.

DaShenLin Pharmaceutical Group Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of DaShenLin Pharmaceutical Group Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how DaShenLin Pharmaceutical Group Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing DaShenLin Pharmaceutical Group Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

DaShenLin Pharmaceutical Group Co Stock Price History
DateDaShenLin Pharmaceutical Group Co Price
8/13/202617.94 CNY
8/12/202618.28 CNY
8/11/202618.86 CNY
8/10/202618.25 CNY
8/7/202617.51 CNY
8/6/202617.91 CNY
8/5/202618.26 CNY
8/4/202618.59 CNY
8/3/202618.50 CNY
7/31/202618.90 CNY
7/30/202619.13 CNY
7/29/202619.01 CNY
7/28/202618.84 CNY
7/27/202618.61 CNY
7/24/202618.40 CNY
7/23/202618.73 CNY
7/22/202618.76 CNY
7/21/202618.91 CNY
7/20/202618.75 CNY
7/17/202618.94 CNY
7/16/202619.25 CNY
7/15/202619.25 CNY
7/14/202619.68 CNY
7/13/202618.12 CNY
7/10/202617.65 CNY
7/9/202617.65 CNY
7/8/202617.81 CNY
7/7/202617.48 CNY
7/6/202617.20 CNY
7/3/202617.02 CNY
7/2/202616.29 CNY
7/1/202616.15 CNY
6/30/202615.03 CNY
6/29/202615.48 CNY
6/26/202614.80 CNY
6/25/202615.92 CNY
6/24/202615.91 CNY
6/23/202615.99 CNY
6/22/202615.59 CNY
6/18/202616.02 CNY
6/17/202616.05 CNY
6/16/202616.42 CNY
6/15/202616.76 CNY
6/12/202617.07 CNY
6/11/202616.38 CNY
6/10/202616.45 CNY
6/9/202615.84 CNY
6/8/202615.79 CNY
6/5/202616.21 CNY
6/4/202616.12 CNY
6/3/202616.19 CNY
6/2/202616.67 CNY
6/1/202616.66 CNY
5/29/202616.55 CNY
5/28/202616.27 CNY
5/27/202616.54 CNY
5/26/202616.94 CNY
5/25/202616.92 CNY
5/22/202617.50 CNY
5/21/202617.81 CNY
5/20/202617.79 CNY
5/19/202617.79 CNY
5/18/202617.79 CNY
5/15/202618.81 CNY
5/14/202618.77 CNY
5/13/202618.75 CNY
5/12/202618.76 CNY
5/11/202618.80 CNY
5/8/202618.55 CNY
5/7/202618.49 CNY
5/6/202618.67 CNY
4/30/202618.72 CNY
4/29/202619.35 CNY
4/28/202618.75 CNY
4/27/202618.60 CNY
4/24/202618.19 CNY
4/23/202617.98 CNY
4/22/202617.79 CNY
4/21/202617.77 CNY
4/20/202617.53 CNY
4/17/202617.39 CNY
4/16/202617.52 CNY
4/15/202617.45 CNY
4/14/202617.06 CNY
4/13/202617.25 CNY
4/10/202617.76 CNY
4/9/202617.42 CNY
4/8/202617.85 CNY
4/7/202617.66 CNY
4/3/202617.83 CNY
4/2/202617.95 CNY
4/1/202618.20 CNY
3/31/202617.78 CNY
3/30/202617.58 CNY
3/27/202617.56 CNY
3/26/202617.44 CNY
3/25/202617.56 CNY
3/24/202617.27 CNY
3/23/202616.98 CNY
3/20/202618.11 CNY
3/19/202618.20 CNY
3/18/202618.75 CNY
3/17/202618.90 CNY
3/16/202618.93 CNY
3/13/202619.07 CNY
3/12/202619.20 CNY
3/11/202619.33 CNY
3/10/202619.29 CNY
3/9/202619.45 CNY
3/6/202619.83 CNY
3/5/202619.61 CNY
2/27/202619.63 CNY
2/26/202619.67 CNY
2/25/202619.69 CNY
2/13/202619.21 CNY
2/12/202619.49 CNY
2/11/202619.36 CNY
2/10/202619.58 CNY
2/9/202619.72 CNY
2/6/202619.69 CNY
2/5/202619.94 CNY
2/4/202619.86 CNY
2/3/202619.26 CNY
2/2/202619.05 CNY
1/30/202620.05 CNY
1/29/202620.25 CNY
1/28/202619.88 CNY
1/27/202619.86 CNY
1/26/202620.74 CNY
1/23/202621.30 CNY
1/22/202619.91 CNY
1/21/202619.54 CNY
1/20/202619.40 CNY
1/19/202619.83 CNY
1/16/202619.00 CNY
1/15/202618.74 CNY
1/14/202618.71 CNY
1/13/202618.53 CNY
1/12/202618.53 CNY
1/9/202618.41 CNY
1/8/202618.16 CNY
1/7/202618.16 CNY
1/6/202618.04 CNY
1/5/202617.78 CNY
12/31/202517.63 CNY
12/30/202517.69 CNY
12/29/202517.61 CNY
12/26/202518.11 CNY
12/25/202518.07 CNY
12/24/202517.96 CNY
12/23/202517.92 CNY
12/22/202518.08 CNY
12/19/202518.46 CNY
12/18/202518.24 CNY
12/17/202517.68 CNY
12/16/202517.39 CNY
12/15/202517.34 CNY
12/12/202517.22 CNY
12/11/202517.20 CNY
12/10/202517.46 CNY
12/9/202517.48 CNY
12/8/202517.47 CNY
12/5/202517.83 CNY
12/4/202517.91 CNY
12/3/202518.19 CNY
12/2/202518.03 CNY
12/1/202518.30 CNY
11/28/202517.65 CNY
11/27/202517.67 CNY
11/26/202517.84 CNY
11/25/202517.79 CNY
11/24/202517.53 CNY
11/21/202517.54 CNY
11/20/202517.69 CNY
11/19/202518.09 CNY
11/18/202518.06 CNY
11/17/202518.16 CNY
11/14/202518.61 CNY
11/13/202518.86 CNY
11/12/202519.50 CNY
11/11/202518.63 CNY
11/10/202518.66 CNY
11/7/202518.28 CNY
11/6/202518.02 CNY
11/5/202518.49 CNY
11/4/202518.29 CNY
11/3/202518.14 CNY
10/31/202518.35 CNY
10/30/202518.21 CNY
10/29/202518.17 CNY
10/28/202518.27 CNY
10/27/202518.57 CNY
10/24/202518.76 CNY
10/23/202519.20 CNY
10/22/202518.93 CNY
10/21/202518.70 CNY
10/20/202518.38 CNY
10/17/202517.47 CNY
10/16/202517.33 CNY
10/15/202517.12 CNY
10/14/202516.85 CNY
10/13/202516.63 CNY
10/10/202516.74 CNY
10/9/202516.61 CNY
9/30/202516.49 CNY
9/29/202516.72 CNY
9/26/202517.11 CNY
9/25/202517.11 CNY
9/24/202517.23 CNY
9/23/202517.09 CNY
9/22/202517.00 CNY
9/19/202517.34 CNY
9/18/202517.43 CNY
9/17/202517.66 CNY
9/16/202517.22 CNY
9/15/202517.32 CNY
9/12/202517.39 CNY
9/11/202517.55 CNY
9/10/202517.34 CNY
9/9/202517.72 CNY
9/8/202517.69 CNY
9/5/202517.17 CNY
9/4/202517.11 CNY
9/3/202516.92 CNY
9/2/202517.25 CNY
9/1/202516.96 CNY
8/29/202516.89 CNY
8/28/202517.12 CNY
8/27/202516.76 CNY
8/26/202517.15 CNY
8/25/202517.11 CNY
8/22/202517.32 CNY
8/21/202517.25 CNY
8/20/202517.19 CNY
8/19/202517.16 CNY
8/18/202517.14 CNY
Access this data via the Eulerpool API
Get Free API Key

DaShenLin Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
16.76 B CNY
1.13 B CNY
791.23 M CNY
Jan 1, 2022
21.25 B CNY
1.58 B CNY
1.04 B CNY
Jan 1, 2023
24.53 B CNY
1.78 B CNY
1.17 B CNY
Jan 1, 2024
26.50 B CNY
1.53 B CNY
914.76 M CNY
Jan 1, 2025 (e)
27.39 B CNY
1.87 B CNY
1.19 B CNY
Jan 1, 2026 (e)
29.86 B CNY
2.04 B CNY
1.47 B CNY
Jan 1, 2027 (e)
32.86 B CNY
2.25 B CNY
1.69 B CNY
Jan 1, 2028 (e)
36.24 B CNY
2.48 B CNY
1.93 B CNY

DaShenLin Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 10:50 PM
 
REVENUEB CNY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CNY
EBITB CNY
EBIT MARGIN%
NET INCOMEB CNY
NET INCOME GROWTH%
DIV.CNY
DIV. GROWTH%
SHARESB
201420152016201720182019202020212022202320242025e2026e2027e2028e
4.555.276.277.428.8611.1414.5816.7621.2524.5326.5027.3929.8632.8636.24
–15.8419.1618.2819.3825.7630.8914.9226.7915.458.013.379.0210.0610.28
40.1540.8540.1540.1441.5739.4038.3338.0337.7535.6134.2534.2534.2534.2534.25
1.832.152.522.983.684.395.596.378.028.749.079.3810.2311.2512.41
0.430.560.590.640.720.911.391.131.581.781.531.872.042.252.48
9.4810.589.348.588.078.179.546.777.457.245.776.846.846.846.84
0.270.400.430.480.530.701.060.791.041.170.911.191.471.691.93
–48.508.8610.4712.0032.1451.07-25.5230.8512.66-21.6129.9823.3215.1514.46
––––0.600.460.500.670.420.500.620.650.740.84–
–––––-23.338.7034.00-37.3119.0524.004.8413.8513.51–
0.510.600.670.710.750.800.791.141.141.131.131.131.131.131.13
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales DaShenLin Pharmaceutical Group Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue DaShenLin Pharmaceutical Group Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare DaShenLin Pharmaceutical Group Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares DaShenLin Pharmaceutical Group Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against DaShenLin Pharmaceutical Group Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

DaShenLin Pharmaceutical Group Co stock margins

The DaShenLin Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DaShenLin Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DaShenLin Pharmaceutical Group Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
38.33 %
9.54 %
7.28 %
Jan 1, 2021
38.03 %
6.77 %
4.72 %
Jan 1, 2022
37.76 %
7.45 %
4.87 %
Jan 1, 2023
35.61 %
7.25 %
4.76 %
Jan 1, 2024
34.25 %
5.77 %
3.45 %
Jan 1, 2025 (e)
34.25 %
6.84 %
4.34 %
Jan 1, 2026 (e)
34.25 %
6.84 %
4.91 %
Jan 1, 2027 (e)
34.25 %
6.84 %
5.13 %

DaShenLin Pharmaceutical Group Co Stock Revenue, EBIT, Earnings per Share

The DaShenLin Pharmaceutical Group Co earnings per share therefore indicates how much revenue DaShenLin Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
18.51 CNY
1.77 CNY
1.35 CNY
Jan 1, 2021
14.71 CNY
1.00 CNY
0.69 CNY
Jan 1, 2022
18.63 CNY
1.39 CNY
0.91 CNY
Jan 1, 2023
21.66 CNY
1.57 CNY
1.03 CNY
Jan 1, 2024
23.46 CNY
1.35 CNY
0.81 CNY
Jan 1, 2025 (e)
24.25 CNY
1.66 CNY
1.05 CNY
Jan 1, 2026 (e)
26.44 CNY
1.81 CNY
1.30 CNY
Jan 1, 2027 (e)
29.10 CNY
1.99 CNY
1.49 CNY

DaShenLin Pharmaceutical Group Co business model & stock analysis

DaShenLin Pharmaceutical Group Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

DaShenLin Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio

DaShenLin Pharmaceutical Group Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

DaShenLin Pharmaceutical Group Co shares outstanding

The number of shares of DaShenLin Pharmaceutical Group Co was 1.13 B in 2025. This indicates how many shares DaShenLin Pharmaceutical Group Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
788.00 M Stocks
Jan 1, 2021
1.14 B Stocks
Jan 1, 2022
1.14 B Stocks
Jan 1, 2023
1.13 B Stocks
Jan 1, 2024
1.13 B Stocks
Jan 1, 2025 (e)
1.13 B Stocks
Jan 1, 2026 (e)
1.13 B Stocks
Jan 1, 2027 (e)
1.13 B Stocks

DaShenLin Pharmaceutical Group Co stock splits

In DaShenLin Pharmaceutical Group Co's history, there have been no stock splits.

DaShenLin Pharmaceutical Group Co Dividend History

9 years of dividend payments · 3 consecutive increases

YearAnnual DividendYoY ChangePayments
20260.49CNYYTD—1×
Jun 26, 20260.49CNY↑ 44.1%1/1
20250.65CNY↑ 4.8%2×
Jun 19, 20250.31CNY 0.0%1/2
Nov 6, 20250.34CNY↑ 9.7%2/2
20240.62CNY↑ 24.0%2×
20230.50CNY↑ 20.0%1×
20220.42CNY↓ 37.5%1×
20210.67CNY↑ 33.3%1×
20200.50CNY↑ 8.3%1×
20190.46CNY↓ 23.1%1×
20180.60CNY—1×

DaShenLin Pharmaceutical Group Co dividend history and estimates

In 2025, DaShenLin Pharmaceutical Group Co paid a dividend amounting to 0.65 CNY. Dividend means that DaShenLin Pharmaceutical Group Co distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
0.50 CNY
0.00 CNY
Jan 1, 2021
0.67 CNY
0.00 CNY
Jan 1, 2022
0.42 CNY
0.00 CNY
Jan 1, 2023
0.50 CNY
0.00 CNY
Jan 1, 2024
0.62 CNY
0.00 CNY
Jan 1, 2025
0.65 CNY
0.00 CNY
Jan 1, 2026 (e)
0.00 CNY
0.74 CNY
Jan 1, 2027 (e)
0.00 CNY
0.84 CNY

DaShenLin Pharmaceutical Group Co dividend payout ratio

In 2025, DaShenLin Pharmaceutical Group Co had a payout ratio of 61.78%. The payout ratio indicates the percentage of the company's profits that DaShenLin Pharmaceutical Group Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
25.72 %
Jan 1, 2021
66.65 %
Jan 1, 2022
45.87 %
Jan 1, 2023
58.25 %
Jan 1, 2024
76.54 %
Jan 1, 2025 (e)
61.78 %
Jan 1, 2026 (e)
56.76 %
Jan 1, 2027 (e)
55.91 %

Current DaShenLin Pharmaceutical Group Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
92.86 % (13)
Hold
7.14 % (1)
Sell
0.00 % (0)
12M Price Target
24.48
Last Price
17.91
Currency
CNY
12M Return Potential
36.68 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the DaShenLin Pharmaceutical Group Co stock

60/100
49
Environment
75
Social
56
Governance
E

Environment

20
Scope 1 - Direct Emissions5,220.48
Scope 2 - Indirect emissions from purchased energy14,082.59
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions19,303.07
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees86.27
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

DaShenLin Pharmaceutical Group Co shareholder structure

% Name
2.36194%
Lazard Asset Management, L.L.C.
Lazard Asset Management, L.L.C.
1.04042%
FIL Investment Management (Hong Kong) Limited
FIL Investment Management (Hong Kong) Limited
0.39995%
FIL Investment Management (Singapore) Ltd.
FIL Investment Management (Singapore) Ltd.
0.17828%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.13468%
Fidelity International
Fidelity International
0.11870%
Mercer Investments LLC
Mercer Investments LLC

DaShenLin Pharmaceutical Group Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
33.0%
Float Shares
-
Shares Outstanding
-

DaShenLin Pharmaceutical Group Co Executives and Management Board

12 members · avg. age 50 · 17 % women

CC

Mr. Changcheng Chen (40)

Deputy General Manager, General Manager - Center

2.09 M CNY

Management

XJ

Ms. Xin Jiang (54)

Deputy General Manager

2.03 M CNY
TK

Mr. Tuoji Ke (29)

Deputy General Manager, General Manager - Shenzhen Operations Region

1.81 M CNY
HC

Mr. Hong Chen (46)

Deputy General Manager

1.46 M CNY
GP

Mr. Guangzhi Peng (42)

Chief Financial Officer, Secretary of the Board

889,100.00 CNY

Board of Directors

YK

Mr. Yunfeng Ke (57)

Chairman of the Board · since 2016

2.49 M CNY
GK

Mr. Guoqiang Ke (42)

General Manager, Director

2.31 M CNY
QT

Ms. Qunfei Tan (57)

Deputy General Manager, Director · since 2016

2.05 M CNY
LL

Mr. Liping Lu (51)

Independent Director

80,000.00 CNY
ZS

Mr. Zuyao Su (61)

Independent Director

80,000.00 CNY
GL

Mr. Guochang Liu (60)

Independent Director

73,400.00 CNY

Frequently asked questions about DaShenLin Pharmaceutical Group Co

Analysts currently set an average price target of 24.77 CNY for the DaShenLin Pharmaceutical Group Co stock (median: 24.48 CNY), implying +38.3 % versus the latest price. The consensus is based on 14 analyst ratings.

DaShenLin Pharmaceutical Group Co Analyst Price Targets 2026

14 analysts currently rate the DaShenLin Pharmaceutical Group Co stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect DaShenLin Pharmaceutical Group Co to generate revenue of 29.86 B CNY and earnings per share of 1.30 CNY.

DaShenLin Pharmaceutical Group Co Analyst Price Targets 2026

Converted at the current exchange rate, the DaShenLin Pharmaceutical Group Co share trades at 2.30 EUR (17.94 CNY).

No history available for DaShenLin Pharmaceutical Group Co.

The expected revenue of DaShenLin Pharmaceutical Group Co is 29.86 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of DaShenLin Pharmaceutical Group Co is 1.47 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of DaShenLin Pharmaceutical Group Co is currently 13.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DaShenLin Pharmaceutical Group Co stock.

The price-to-sales ratio (P/S) of DaShenLin Pharmaceutical Group Co is currently 0.68. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DaShenLin Pharmaceutical Group Co stock.

The Eulerpool Quality Score for DaShenLin Pharmaceutical Group Co is 8/10.

The ISIN of DaShenLin Pharmaceutical Group Co is CNE100002RG2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of DaShenLin Pharmaceutical Group Co is 603233.SS. The ticker symbol is used to trade DaShenLin Pharmaceutical Group Co shares on the stock exchange.

Over the past 12 months, DaShenLin Pharmaceutical Group Co paid a dividend of 0.62 CNY . This corresponds to a dividend yield of about 3.46 %. For the coming 12 months, DaShenLin Pharmaceutical Group Co is expected to pay a dividend of 0.84 CNY.

The current dividend yield of DaShenLin Pharmaceutical Group Co is 3.46 %.

DaShenLin Pharmaceutical Group Co pays a dividend, distributed in the months of , , , .

DaShenLin Pharmaceutical Group Co paid dividends every year for the past 8 years.

For the upcoming 12 months, dividends amounting to 0.84 CNY are expected. This corresponds to a dividend yield of 4.66 %.

DaShenLin Pharmaceutical Group Co is assigned to the 'Non-cyclical consumption' sector.

In the year 2025, DaShenLin Pharmaceutical Group Co distributed 0.62 CNY as dividends.

The dividends of DaShenLin Pharmaceutical Group Co are distributed in CNY.

All fundamentals and in-depth analysis of DaShenLin Pharmaceutical Group Co

Our stock analysis for DaShenLin Pharmaceutical Group Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DaShenLin Pharmaceutical Group Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Revenue→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Net Income→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co P/E→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co P/S→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co EBIT→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Dividend→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Directors Dealings→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Stocks→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Market capitalization→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Debt→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Liabilities→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Equity→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co AAQS→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Employees→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co ROE→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co ROA→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co ROCE→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co News→
DaShenLin Pharmaceutical Group Co Stock
DaShenLin Pharmaceutical Group Co Analyst Price Targets→

Non-cyclical consumption Stocks

Datiware Maritime InfraDarling IngredientsDavide Campari MilanoDaodaoquan Grain and Oil CoDavis CommoditiesDanoneDawushan Farm Technology CoDangee DumsDcm Shriram IndustriesDalmia Bharat Sugar and IndustriesDDC EnterpriseDaisui CoAll Stocks A–Z →